MDM2 and cancer: The advantages of ATSP-7041 and ALRN-6924 dual inhibition of MDMX and MDM2 were shown by head-to-head comparison with selective MDM2 inhibitors, RG7112 and RG7388, in cancers that overexpress MDMX, where these dual-peptide-based inhibitors showed superior activity [97,98].